|
|
Blood, Vol. 109, Issue 10, 4151-4157, May 15, 2007
Ancestry and pharmacogenetics of antileukemic drug toxicity
Blood Kishi et al.
109: 4151
Supplemental materials for: Kishi et al, Vol 109, Issue 10, 4151-4157
Files in this Data Supplement:
- Table S1. Relation between demographic factors and toxicity (PDF, 97.3 KB) -
Significant associations with P < .05 are underlined. Blanks (—) are invalid, as no event was recorded in one of the analyzed cells. GI indicates gastrointestinal; HDMTX, high-dose methotrexate; LDMTX, low-dose methotrexate; 6MP, mercaptopurine; ND, not done; LCL, lower 95% confidence limit; and UCL, upper 95% confidence limit.
- Table S2. Associations between genotypes and toxicity events occurring during the induction period, according to univariate analyses (PDF, 51.7 KB) -
Significant associations with P < .05 are underlined. Blanks (—) are invalid, as no event was recorded in one of the analyzed cells. GI indicates gastrointestinal; LCL, lower 95% confidence limit; and UCL, upper 95% confidence limit.
- Table S3. Associations between genotypes and toxicity events occurring during the consolidation period, according to univariate analyses (PDF, 46.5 KB) -
Significant associations with P < .05 are underlined. Blanks (—) are invalid, as no event was recorded in one of the analyzed cells.
GI indicates gastrointestinal; LCL, lower 95% confidence limit; and UCL, upper 95% confidence limit.
- Table S4. Associations between genotypes and toxicity events occurring during the continuation period, according to univariate analysis (PDF, 20.1 KB) -
Significant associations with P < .05 are underlined. Blanks (—) are invalid, as no event was recorded in one of the analyzed cells. GI indicates gastrointestinal; LCL, lower 95% confidence limit; and UCL, upper 95% confidence limit.
- Table S5. Multigenic functional pathway groupings (PDF, 35.4 KB)
- Table S6. Associations between combined 3 pathway-directed functional groups and toxicity; composition of the groups is defined in main Table 2 (PDF, 76.6 KB) -
Significant associations with P < .05 are underlined. Blanks (—) are invalid as no event was recorded in one of the analyzed cells. GI indicates gastrointestinal; ND, not done; LCL, lower 95% confidence limit; and UCL, upper 95% confidence limit.
- Table S7. P values for the regressions for associations among genotypes (PDF, 116 KB) -
Significant associations with P < .05 are underlined.
- Figure S1. Plasma methotrexate pharmacokinetics differ by the presence of hyperbilirubinemia and by UGT1A1 genotypes (JPG, 38 KB)
-
Average methotrexate clearance (quartiles, 95% confidence intervals, outliers) during continuation was lower in patients who had grade 3 to 4 hyperbilirubinemia (P = .024, adjusting for demographic factors and UGT1A1 genotype) (left) and in patients with the low activity UGT1A1 7/7 genotype (P = .028, adjusting for demographic factors) (right).
| |
